Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy
F M Russell, P V Licciardi, A Balloch, V Biaukula, L Tikoduadua, J R Carapetis, J Nelson, A W J Jenney, L Waqatakirewa, S Colquhoun, Y B Cheung, M L K Tang, E K Mulholland, F M Russell, P V Licciardi, A Balloch, V Biaukula, L Tikoduadua, J R Carapetis, J Nelson, A W J Jenney, L Waqatakirewa, S Colquhoun, Y B Cheung, M L K Tang, E K Mulholland
Abstract
Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.
Trial registration: ClinicalTrials.gov NCT00170612.
Copyright 2010 Elsevier Ltd. All rights reserved.
Figures
Source: PubMed